Pure Global AI
NCT06377202Recruiting

Long-Term Follow-Up Safety Study of Subjects Treated With SynKIR-110 in Cancer Studies

Long-Term Follow-Up Safety Study of Subjects Treated With SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Cancer Studies
Verismo TherapeuticsClinicalTrials.gov
Verified
Study focus
Disease/Condition
Cancer
Study type
Observational
Sponsor & location
Primary sponsor
Verismo Therapeutics
Location
Philadelphia, United States of America
Timeline & enrollment
Phase
N/A
Start date
Nov 15, 2023
End date
Dec 15, 2038
Enrollment
100 participants
Primary outcome

Number of subjects with treatment related adverse events as assessed by CTCAE v5.0

Summary

The primary objective of this study is to evaluate the long-term safety of SynKIR- 110
 administered to adult subjects with solid tumors expressing mesothelin.

ICD-10 classifications
Carcinoid syndromeOther chemotherapyCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Prepuce
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06377202
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06377202 through Pure Global AI's free database. This phase not specified trial is sponsored by Verismo Therapeutics and is currently Recruiting. The study focuses on Cancer. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.